Benefits
Heartburn: the relief figures come from two small studies published only in a patent
The figures behind limonene's heartburn reputation come from two small studies that were never published in a journal. They are described only in US patent 6,420,435 B1, 'Method for treating gastrointestinal disorders', granted to Joe S. Wilkins Jr. in July 2002. The first, 19 people with long-standing heartburn taking 1,000 mg daily or every other day, had no control group. The second was a double-blind comparison in 13 people, 7 on d-limonene and 6 on placebo. So '86 percent complete relief' describes six individuals in a document written by the inventor in support of a patent claim, and no version of either study has been through peer review. Mechanism likely combines gastric acid neutralization, support of normal peristalsis, and potential lower esophageal sphincter tone modulation. The proposed mechanism (acid neutralisation, support of normal peristalsis) has not been demonstrated in a controlled human study. Proton pump inhibitors and H2 blockers have far stronger evidence for reflux. One published case report describes a woman whose reflux symptoms returned on each of three 20-day courses of a proprietary d-limonene product when her acid-suppressing drug was withdrawn.
Oncology research on d-limonene (not a supplement use)
D-limonene is not a treatment for any disease and should not be taken for one. The single oncology study, a 1998 UK phase I trial in 32 people with advanced refractory tumours, existed to find the maximum tolerated dose and to measure blood levels. Oral d-limonene was given at 0.5-12 g/m2/day in 21-day cycles. MTD was 8 g/m2/day; one partial response in a breast cancer patient at 8 g/m2/day was maintained 11 months, and 3 colorectal cancer patients had prolonged stable disease. Tumor levels of monoterpenes were detected. In the 10-patient phase II breast cancer extension at 8 g/m2/day, the authors recorded no responses at all. A later open-label study gave 2 g of oral limonene daily for two to six weeks to 43 women awaiting breast cancer surgery: limonene concentrated in breast tissue and tumour cyclin D1 fell by 22 percent, but there was no meaningful change in the other blood markers measured and IGF-1, a growth factor whose elevation is linked to higher cancer risk, rose slightly. There has still been no placebo-controlled trial, and these doses are far above any supplement serving.
Blood inflammation markers in older adults (one open-label trial, main endpoint not met)
In the RISTOMED trial, 125 healthy adults aged 65 to 85 followed a Mediterranean-style diet for 56 days and were randomised, open-label, to that diet alone or to the diet plus one of three supplements. The trial's stated primary outcome was a fall in high-sensitivity CRP, and that did not happen in any arm (Kruskal-Wallis p = 0.86). Among the secondary markers, the 30 people in the d-limonene arm (about 10 mg/kg/day of an orange-peel monoterpene softgel) had a larger fall in fibrinogen than the diet-only and argan-oil arms (p = 0.04). Sedimentation rate fell significantly in every arm including diet alone, and the falls in glucose, insulin and HOMA-IR were within-arm changes from baseline in a trial where the diet-only arm also had a significant glucose fall. Mechanism involves NF-κB inhibition, COX-2 downregulation, and Th1/Th2 balance modulation. The NF-kB and COX-2 mechanisms come from cell and rodent work, not from measurements in people, and no symptom or disease outcome was measured in the trial.
Gallstone solvent: a hospital procedure, not an oral supplement use
This has nothing to do with swallowing a capsule. Between the 1970s and the 1990s, mainly in Japan, surgeons instilled limonene-based solvents such as GS-100 directly into the gallbladder or bile duct through a catheter to dissolve cholesterol stones, and the approach was largely replaced by keyhole gallbladder surgery. Taking oral d-limonene does not dissolve gallstones.
Mechanism of action
Gastric acid neutralization and peristalsis support
Acid neutralisation and support of normal peristalsis are the mechanisms proposed in a 2007 review for the heartburn use. They are proposals: neither has been measured in a controlled human study of limonene, and the lower oesophageal sphincter effect comes from animal work. The exact molecular target is not defined. Proposals include direct mucosal coating, modulation of gastric motility, or effects on TRPA1/TRPV1 channels in the oesophagus, none of which has been tested in a human study.
Protein farnesylation inhibition (a laboratory finding)
D-limonene and metabolites (perillyl alcohol, perillic acid) inhibit protein farnesylation, a post-translational modification required for Ras oncoprotein membrane anchoring and signaling. This has been observed in cell culture and rodent tumour models, and it is why limonene was tested in oncology at all. It has never been shown to prevent or treat cancer in people, and the exposures involved are far above what a supplement serving delivers.
Antioxidant and anti-inflammatory mechanisms (cell and animal work)
Limonene scavenges ROS directly and induces phase 2 detoxification enzymes (glutathione-S-transferase, NAD(P)H:quinone oxidoreductase) via Nrf2 activation. Inhibits NF-κB nuclear translocation, reducing pro-inflammatory cytokine production. Limonene concentrates in fatty tissue, which is a pharmacokinetic observation and not a demonstrated antioxidant benefit. No study has measured an antioxidant outcome in people taking oral d-limonene.
TRPA1/TRPV1 channel modulation (taste/sensation)
D-limonene activates and desensitizes TRPA1 and TRPV1 channels, contributing to its sensory effects (the bright citrus 'tingle') and potentially explaining anti-nociceptive effects observed in animal models. May contribute to GI motility effects through enteric neuronal TRP channels.
Clinical trials
Phase I dose-escalation with limited phase II expansion (Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC 1998, Cancer Chemother Pharmacol 42(2):111-117, doi:10.1007/s002800050793).
32 patients with refractory solid tumors completing 99 courses of D-limonene 0.5-12 g/m²/day orally in 21-day cycles. Pharmacokinetics analyzed by LC-MS. Additional 10 breast cancer patients received 15 cycles at 8 g/m²/day. Intratumoral monoterpene levels measured in 2 patients.
MTD established at 8 g/m²/day; nausea, vomiting, diarrhea were dose-limiting toxicities. One partial response in breast cancer patient on 8 g/m²/day maintained for 11 months. Three colorectal cancer patients had prolonged stable disease. Monoterpene metabolites (perillic acid, dihydroperillic acid) accumulated in plasma; intratumoral levels achieved. The paper also reports that there were no responses in the phase II study. The authors concluded that d-limonene was well tolerated at doses that may have clinical activity and that the toxicity profile supported further evaluation. The only later oral study, an open-label 2013 trial in 43 women awaiting breast cancer surgery at 2 g/day, measured tissue and blood markers rather than any clinical outcome. These are chemotherapy dose-finding doses and bear no relation to a supplement serving.
Comprehensive review (Sun J 2007, Altern Med Rev 12(3):259-264).
Comprehensive review of d-limonene human safety data and clinical applications including GERD/heartburn, gallstones, and cancer chemoprevention.
Established that d-limonene has demonstrated low toxicity in humans after single and repeated dosing for up to one year. The renal tubular tumours seen in male rats depend on alpha-2u-globulin, a protein rats have and people do not, so they do not translate to humans. Female rats and mice of both genders show no renal tumor risk. The 'renal cancer in rats' issue is therefore not a human safety concern. It also restates the cholesterol-dissolving property, which in practice meant instilling solvent into the gallbladder through a catheter rather than swallowing it, and the heartburn figures, which trace back to an unpublished patent document.
Unpublished studies described in US patent 6,420,435 B1, 'Method for treating gastrointestinal disorders', inventor Joe S. Wilkins Jr., filed October 2000 and granted 16 July 2002. Neither study has been published in a peer-reviewed journal.
Pilot study 1: 19 patients with chronic GERD/heartburn (≥5 years duration) given 1,000 mg d-limonene every day or every other day. Study 2: 13 people over about 20 days in a double-blind comparison, 7 given d-limonene and 6 given placebo.
Study 1: 32% of participants experienced relief from symptoms after d-limonene administration; 79% reported complete relief at 14 days, and 89% reported either complete relief or only mild symptoms. Study 2: 29% of treatment group had significant relief by day 4; 86% experienced complete relief of all symptoms by day 14 vs placebo. These percentages describe a handful of people: 86 percent of the seven who took d-limonene in study 2 is six individuals. Study 1 had no control group, both studies were short, neither was peer reviewed, and the document reporting them was written by the patent's inventor in support of a commercial claim. No controlled trial of d-limonene for reflux has been published.